Obstet Gynecol:口服或阴道米索前列醇用于分娩启动与剖宫产风险

2019-06-16 xing.T MedSci原创

由此可见,与阴道米索前列醇相比,口服米索前列醇可能与剖宫产风险增加和阴道分娩时间延长有关。

近日,妇产科权威杂志Obstetrics and Gynecology上发表了一研究文章,研究人员旨在评估与阴道米索前列醇相比,超重人群口服米索前列醇促进宫颈成熟是否会增加剖宫产风险并延长阴道分娩时间。

这项单中心、回顾性队列研究在三级医疗教学医疗中心进行,并将阴道米索前列醇分娩诱导结局与口服米索前列醇的结局进行比较。2013-2014年使用25ug阴道米索前列醇的分娩诱导与2014-2015年50ug口服米索前列醇进行比较。主要结局是剖腹产。次要结局包括阴道分娩时间、子宫快速收缩、母体出血和复合不良新生儿结局。研究人员使用标准统计检验分析人口统计学和结局。建立了针对潜在混杂因素的多变量回归模型,并将调整后的比值比(aOR)作为效应度量指标。

138名女性采用口服米索前列醇,阴道米索前列醇组有138名女性。在整个队列中,中位数(四分位距离)体重指数为31.7(28.2-36.8),大多数女性(72%)为黑人或西班牙裔种族或种族。口服米索前列醇组剖宫产的频率高于阴道米索前列醇组(32% vs. 21%; P=0.04)。口服米索前列醇后,剖宫产调整后的几率更高(aOR为2.01; 95%CI为1.07-3.76)。在未经产妇女中,剖宫产率在口服米索前列醇组中为21%,在阴道米索前列醇组中为32%(aOR为2.79; 95%CI为1.26-6.19)。与阴道米索前列醇组相比,女性口服口服米索前列醇的阴道分娩时间更长(分别为41小时 vs. 31小时,P=0.01)。阴道米索前列醇更频繁发生快速宫缩(20% vs. 11%; P=0.04)。 

由此可见,与阴道米索前列醇相比,口服米索前列醇可能与剖宫产风险增加和阴道分娩时间延长有关。 

原始出处:
 
Handal-Orefice,et al.Oral or Vaginal Misoprostol for Labor Induction and Cesarean Delivery Risk.Obstetrics & Gynecology.2019.https://journals.lww.com/greenjournal/Abstract/publishahead/Oral_or_Vaginal_Misoprostol_for_Labor_Induction.97689.aspx

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044103, encodeId=601a2044103ba, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 19:37:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934072, encodeId=fc3e19340e2d3, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri May 15 21:37:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011413, encodeId=66682011413e0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Mar 05 14:37:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275180, encodeId=ec4a12e518019, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Tue Jun 18 07:37:00 CST 2019, time=2019-06-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044103, encodeId=601a2044103ba, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 19:37:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934072, encodeId=fc3e19340e2d3, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri May 15 21:37:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011413, encodeId=66682011413e0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Mar 05 14:37:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275180, encodeId=ec4a12e518019, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Tue Jun 18 07:37:00 CST 2019, time=2019-06-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044103, encodeId=601a2044103ba, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 19:37:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934072, encodeId=fc3e19340e2d3, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri May 15 21:37:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011413, encodeId=66682011413e0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Mar 05 14:37:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275180, encodeId=ec4a12e518019, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Tue Jun 18 07:37:00 CST 2019, time=2019-06-18, status=1, ipAttribution=)]
    2020-03-05 yhy100200
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044103, encodeId=601a2044103ba, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 19:37:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934072, encodeId=fc3e19340e2d3, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri May 15 21:37:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011413, encodeId=66682011413e0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Mar 05 14:37:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275180, encodeId=ec4a12e518019, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Tue Jun 18 07:37:00 CST 2019, time=2019-06-18, status=1, ipAttribution=)]
    2019-06-18 linlin2312

相关资讯

J Thromb Haemost:直接口服抗凝药会增加脑肿瘤患者颅内出血风险吗?

2019年1月,发表于《J Thromb Haemost》上的一项研究,考察了脑肿瘤患者直接口服抗凝药(DOACs)的颅内出血(ICH)风险。

微电机:正改变疫苗的给药方式

目前,研究人员开发了一种使用微电机提供口服疫苗的方法,试图摆脱广泛使用的注射途径。

口服索马鲁肽3期临床表现不凡,未来谁主导糖尿病治疗格局?

刚刚结束的ADA年会上公布了一些重要糖尿病药物的晚期临床试验结果,诺和诺德的口服索玛鲁肽看来要成为糖尿病领域的巨无霸。在PIONEER2试验中一日一次口服索玛鲁肽在HbA1C和体重下降两个主要指标击败礼来的SGLT2抑制剂Jardiance。在PIONEER4中一日一次口服索玛鲁肽与自己一日一次注射的利拉鲁肽比显示非劣效性。此前索玛鲁肽也曾在三期临床击败过默沙东的DPP4抑制剂Januvia,

Sci Rep:口服乙肝疫苗即将问世,攻克乙型肝炎我们还有多远?

乙型肝炎是由乙肝病毒(HBV)引起的疾病,在世界各国均有流行,我国属高流行区,椐统计,全球共有20多亿人曾经感染过HBV,目前全球仍有2.57亿乙肝病毒感染者(乙肝表面抗原阳性),而我们与乙肝的斗争也从未停止。

Science:新型口服胰岛素,或将取代传统注射

近日,美国麻省理工学院(MIT)领导的一个研究团队开发了一种可以口服的胰岛素胶囊,有望取代2型糖尿病患者每天必须使用的注射型胰岛素。

专家视角:对口服精神科药物几个问题的解答

经常有病人询问我一些涉及口服精神科药物的问题,如某种药物是否可以空腹服用?如几种药物联用时,药物是彼此分开服用,还是可以混在一起服用?是否能用茶水送服药物?